{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:05:47Z","timestamp":1788195947329,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ICI20\/00118"],"award-info":[{"award-number":["ICI20\/00118"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0017\/0021"],"award-info":[{"award-number":["RD21\/0017\/0021"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01792"],"award-info":[{"award-number":["PI20\/01792"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06899-0","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T13:52:03Z","timestamp":1755611523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies"],"prefix":"10.1186","volume":"23","author":[{"given":"Bel\u00e9n","family":"Sierro-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Guijarro-Albaladejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Fern\u00e1ndez-Cisnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Rodr\u00edguez-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Hern\u00e1ndez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"de la Rosa-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Carrasco-Brocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Lara-Chica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Escamilla-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Mu\u00f1oz-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jose","family":"Garc\u00eda-C\u00f3zar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3616-6101","authenticated-orcid":false,"given":"Jose Antonio","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3041-9860","authenticated-orcid":false,"given":"Estefan\u00eda","family":"Garc\u00eda-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"6899_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024;30:338\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02767-w.","journal-title":"Nat Med"},{"key":"6899_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"6899_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145\u201361.","journal-title":"Nat Rev Cancer"},{"key":"6899_CR4","doi-asserted-by":"publisher","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. 2021. https:\/\/doi.org\/10.1016\/S0140-6736(21)01222-8","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"6899_CR5","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22","volume":"41","author":"TW Laetsch","year":"2022","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Andr A, Baruchel A, Boyer M, De Moerloose B, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2022;41:1664\u20139. https:\/\/doi.org\/10.1200\/JCO.22.","journal-title":"J Clin Oncol"},{"key":"6899_CR6","doi-asserted-by":"crossref","unstructured":"Martin T, Saad ;, Usmani Z, Berdeja JG, Agha ; Mounzer, Cohen AD, Hari P, Avigan D, Deol A, Htut M, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. 2022. 1265\u20131274.","DOI":"10.1200\/JCO.22.00842"},{"key":"6899_CR7","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29:2286\u201394. https:\/\/doi.org\/10.1038\/s41591-023-02496-0.","journal-title":"Nat Med"},{"key":"6899_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13045-024-01530-Z\/FIGURES\/4","volume":"17","author":"J Xu","year":"2024","unstructured":"Xu J, Wang BY, Yu SH, Chen SJ, Yang SS, Liu R, Chen LJ, Hou J, Chen Z, Zhao WH, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024;17:1\u201313. https:\/\/doi.org\/10.1186\/S13045-024-01530-Z\/FIGURES\/4.","journal-title":"J Hematol Oncol"},{"key":"6899_CR9","doi-asserted-by":"publisher","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, Fern\u00e1ndez de Larrea C, Mart\u00ednez-L\u00f3pez J, Moreau P, Touzeau C, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med 2023;389:335\u2013347. https:\/\/doi.org\/10.1056\/nejmoa2303379","DOI":"10.1056\/nejmoa2303379"},{"key":"6899_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/nejmoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/doi.org\/10.1056\/nejmoa2024850.","journal-title":"N Engl J Med"},{"key":"6899_CR11","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3390\/CANCERS15041003","volume":"15","author":"V Wang","year":"2023","unstructured":"Wang V, Gauthier M, Decot V, Reppel L, Bensoussan D. Systematic review on CAR-T cell clinical trials up to 2022: academic center input. Cancers. 2023;15:1003. https:\/\/doi.org\/10.3390\/CANCERS15041003.","journal-title":"Cancers"},{"key":"6899_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, Van Der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0041-7.","journal-title":"Nat Med"},{"key":"6899_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/S41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739\u201348. https:\/\/doi.org\/10.1038\/S41591-018-0036-4.","journal-title":"Nat Med"},{"key":"6899_CR14","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Nicolas Gonzalez Castro L, Herlopian A, Maus MV, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133:2212\u201321. https:\/\/doi.org\/10.1182\/blood-2018-12-893396.","journal-title":"Blood"},{"key":"6899_CR15","doi-asserted-by":"publisher","unstructured":"Fajgenbaum DC, June CH. Cytokine Storm. 2020;383:2255\u20132273. https:\/\/doi.org\/10.1056\/NEJMRA2026131","DOI":"10.1056\/NEJMRA2026131"},{"key":"6899_CR16","doi-asserted-by":"publisher","unstructured":"Brudno JN, Lam N, Vanasse D, Shen Y, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. https:\/\/doi.org\/10.1038\/s41591-019-0737-3","DOI":"10.1038\/s41591-019-0737-3"},{"key":"6899_CR17","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al. CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123\u201338. https:\/\/doi.org\/10.1172\/JCI85309.","journal-title":"J Clin Invest"},{"key":"6899_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016. https:\/\/doi.org\/10.1126\/scitranslmed.aaf8621.","journal-title":"Sci Transl Med"},{"key":"6899_CR19","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, L\u00f3pez JA, Chen J, Chung D, Harju-Baker S, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy. Blood. 2017;130:2295\u2013306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141.","journal-title":"Blood"},{"key":"6899_CR20","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, et al. Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404\u201319.","journal-title":"Cancer Discov"},{"key":"6899_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/J.JTCT.2022.03.006","volume":"28","author":"SJ Grant","year":"2022","unstructured":"Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, Giri S. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transplant Cell Ther. 2022;28:294\u2013302. https:\/\/doi.org\/10.1016\/J.JTCT.2022.03.006.","journal-title":"Transplant Cell Ther"},{"key":"6899_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2022-005678","author":"A Rotte","year":"2022","unstructured":"Rotte A, Frigault MJ, Ansari A, Gliner B, Heery C, Shah B. Dose-response correlation for CAR-T cells: a systematic review of clinical studies. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/JITC-2022-005678.","journal-title":"J Immunother Cancer"},{"key":"6899_CR23","doi-asserted-by":"publisher","unstructured":"Chohan KL, Siegler EL, Saad \u00b7, Kenderian S. CART AND IMMUNOTHERAPY (M RUELLA AND P HANLEY, SECTION EDITORS) CAR-T cell therapy: the efficacy and toxicity balance. (2023) 18:9\u201318. https:\/\/doi.org\/10.1007\/s11899-023-00687-7","DOI":"10.1007\/s11899-023-00687-7"},{"key":"6899_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2018.00507\/BIBTEX","volume":"9","author":"M Casucci","year":"2018","unstructured":"Casucci M, Falcone L, Camisa B, Norelli M, Porcellini S, Stornaiuolo A, Ciceri F, Traversari C, Bordignon C, Bonini C, et al. Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional car-t cells co-expressing a suicide gene. Front Immunol. 2018;9: 329239. https:\/\/doi.org\/10.3389\/FIMMU.2018.00507\/BIBTEX.","journal-title":"Front Immunol"},{"key":"6899_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2020.00849\/BIBTEX","volume":"10","author":"C Vitale","year":"2020","unstructured":"Vitale C, Strati P. CAR T-cell therapy for B-cell non-hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front Oncol. 2020;10: 532324. https:\/\/doi.org\/10.3389\/FONC.2020.00849\/BIBTEX.","journal-title":"Front Oncol"},{"key":"6899_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/S13402-024-00984-0","author":"B Sierro-Mart\u00ednez","year":"2024","unstructured":"Sierro-Mart\u00ednez B, Escamilla-G\u00f3mez V, P\u00e9rez-Ortega L, Guijarro-Albaladejo B, Hern\u00e1ndez-D\u00edaz P, de la Rosa-Garrido M, Lara-Chica M, Rodr\u00edguez-Gil A, Reguera-Ortega JL, Sanoja-Flores L, et al. Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features. Cell Oncol. 2024. https:\/\/doi.org\/10.1007\/S13402-024-00984-0.","journal-title":"Cell Oncol"},{"key":"6899_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0669-4","author":"MD Agostino","year":"2020","unstructured":"Agostino MD, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma\u202f: can we do better? Leukemia. 2020. https:\/\/doi.org\/10.1038\/s41375-019-0669-4.","journal-title":"Leukemia"},{"key":"6899_CR28","unstructured":"Porter DL, Hwang W-T, Frey N V, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. www.ScienceTranslationalMedicine.org"},{"key":"6899_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Maryalice SS, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.56.2025.","journal-title":"J Clin Oncol"},{"key":"6899_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014. https:\/\/doi.org\/10.1126\/scitranslmed.3008226.","journal-title":"Sci Transl Med"},{"key":"6899_CR31","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"key":"6899_CR32","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1074\/JBC.M115.675033","volume":"291","author":"S Majdoul","year":"2016","unstructured":"Majdoul S, Seye AK, Kichler A, Holic N, Galy A, Bechinger B, Fenard D. Molecular determinants of vectofusin-1 and its derivatives for the enhancement of lentivirally mediated gene transfer into hematopoietic stem\/progenitor cells. J Biol Chem. 2016;291:2161\u20139. https:\/\/doi.org\/10.1074\/JBC.M115.675033.","journal-title":"J Biol Chem"},{"key":"6899_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/J.OMTM.2019.03.003","volume":"13","author":"A Jamali","year":"2019","unstructured":"Jamali A, Kapitza L, Schaser T, Johnston ICD, Buchholz CJ, Hartmann J. Highly efficient and selective CAR-gene transfer using CD4- and CD8-targeted lentiviral vectors. Mol Ther Methods Clin Dev. 2019;13:371\u20139. https:\/\/doi.org\/10.1016\/J.OMTM.2019.03.003.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"6899_CR34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492\u20139. https:\/\/doi.org\/10.1038\/ni.2035.","journal-title":"Nat Immunol"},{"key":"6899_CR35","doi-asserted-by":"publisher","first-page":"1265255","DOI":"10.3389\/FIMMU.2023.1265255\/BIBTEX","volume":"14","author":"J Ma","year":"2023","unstructured":"Ma J, Yan S, Zhao Y, Yan H, Zhang Q, Li X. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells. Front Immunol. 2023;14:1265255. https:\/\/doi.org\/10.3389\/FIMMU.2023.1265255\/BIBTEX.","journal-title":"Front Immunol"},{"key":"6899_CR36","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1073\/pnas.0801497105","volume":"105","author":"SD Blackburn HSGFEW","year":"2008","unstructured":"SD Blackburn HSGFEW. Selective expansion of a subset of exhausted CD8 T cells by \u03b1PD-L1 blockade. Proc Natl Acad Sci USA. 2008;105:15016\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6899_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/J.CELL.2009.06.036","volume":"138","author":"HW Virgin","year":"2009","unstructured":"Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell. 2009;138:30\u201350. https:\/\/doi.org\/10.1016\/J.CELL.2009.06.036.","journal-title":"Cell"},{"key":"6899_CR38","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581\u201390. https:\/\/doi.org\/10.1038\/nm.3838.","journal-title":"Nat Med"},{"key":"6899_CR39","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","volume":"17","author":"A Ajina","year":"2018","unstructured":"Ajina A, Maher J. Strategies to address chimeric antigen receptor tonic signaling. Mol Cancer Ther. 2018;17:1795\u2013815. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-1097.","journal-title":"Mol Cancer Ther"},{"key":"6899_CR40","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1126\/sciadv.abo0514","volume":"8","author":"P Rodriguez-Marquez","year":"2022","unstructured":"Rodriguez-Marquez P, Calleja-Cervantes ME, Serrano G, Oliver-Caldes A, Palacios-Berraquero ML, Martin-Mallo A, Calvi\u00f1o C, Espa\u00f1ol-Rego M, Ceballos C, Lozano T, et al. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome. Sci Adv. 2022;8:514.","journal-title":"Sci Adv"},{"key":"6899_CR41","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2023022717","author":"J Kaminski","year":"2024","unstructured":"Kaminski J, Fleming RA, Alvarez-Calderon F, Winschel MB, McGuckin C, Ho EE, Eng F, Rui X, Keskula P, Cagnin L, et al. B-cell-directed CAR-T cell therapy activates CD8+ cytotoxic CARneg bystander T-cells in non-human primates and patients. Blood. 2024. https:\/\/doi.org\/10.1182\/BLOOD.2023022717.","journal-title":"Blood"},{"key":"6899_CR42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.134612","author":"PH Chen","year":"2020","unstructured":"Chen PH, Lipschitz M, Weirather JL, Jacobson C, Armand P, Wright K, Hodi FS, Roberts ZJ, Sievers SA, Rossi J, et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.134612.","journal-title":"JCI Insight"},{"key":"6899_CR43","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1158\/1538-7445.AM2024-3850","volume":"84","author":"W Lee","year":"2024","unstructured":"Lee W, Rose D, Keck JG, Yang J. Abstract 3850: Modeling individual variability in CD19 CAR-T therapy: an in vivo study with PBMC-humanized mice. Cancer Res. 2024;84:3850\u20133850. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-3850.","journal-title":"Cancer Res"},{"key":"6899_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-43656-7","volume":"14","author":"RHY Louie","year":"2023","unstructured":"Louie RHY, Cai C, Samir J, Singh M, Deveson IW, Ferguson JM, Amos TG, McGuire HM, Gowrishankar K, Adikari T, et al. CAR+ and CAR\u2212T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies. Nat Commun. 2023;14:1\u201318. https:\/\/doi.org\/10.1038\/s41467-023-43656-7.","journal-title":"Nat Commun"},{"key":"6899_CR45","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/J.IMMUNI.2011.09.019","volume":"35","author":"P Muranski","year":"2011","unstructured":"Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity. 2011;35:972\u201385. https:\/\/doi.org\/10.1016\/J.IMMUNI.2011.09.019.","journal-title":"Immunity"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06899-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06899-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06899-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:09:05Z","timestamp":1757477345000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06899-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6899"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06899-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Peripheral blood mononuclear cells (PBMCs) were obtained from buffy coats of healthy donors kindly donated by the Regional Centre for Blood Transfusions at Virgen del Roc\u00edo University Hospital, Sevilla (Spain) after written informed consent. Leukapheresis from healthy donors were obtained from the leukapheresis unit of the Virgen del Roc\u00edo University Hospital, Sevilla (Spain) after written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.A.P.S is an advisor or consultant for Novartis, Janssen, Roche, Jazz Pharmaceuticals, Amgen, and Gilead Sciences; reports research support from Novartis, Janssen, Pfizer, Roche, and Takeda; reports travel support from Roche, Gilead Sciences and Janssen; and reports patents, royalties, or other intellectual property from Entourage Bioscience on cannabinoid derivatives. E.G.G has been a consultant to Cellgene and GLS, and received travel grants and\/or speaker fees from Cellgene, Amgen, Janssen. E.G.G is a co-inventor on a patent application on the use of BCMA-CAR T-cell therapy in combination with ATRA, \u201cCombination treatment of BCMA CAR-T and ATRA in multiple myeloma\u201d (WO2021\/209498 A1), that has been filed by the University of W\u00fcrzburg, W\u00fcrzburg, Germany and licensed to T-CURX GmbH, W\u00fcrzburg, Germany.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"942"}}